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in Familial Hypercholesterolemia
The LDL-Density-Gene Effect*Nalini M. Rajamannan, MDC alciﬁc aortic valve disease (CAVD) is themost common indication worldwide forvalve intervention. For years, the mecha-
nism for this calciﬁcation was thought to be due
to a passive degenerative process. However, in the
21st century, the National Heart, Lung, and Blood
Institute of the National Institutes of Health
recognized that CAVD is an active biologic osteo-
genic process (1). Initiation of osteogenesis in
the aortic valve depends on risk factors similar to
those known to promote coronary artery disease,
which cause myoﬁbroblasts to differentiate via an
osteogenic gene activation that results in valve
calciﬁcation (1,2).In this issue of the Journal, a study from the
Netherlands by ten Kate et al. (3) tested the preva-
lence, extent, and risk modiﬁers of CAVD in patients
with heterozygous familial hypercholesterolemia
(he-FH). Clinically, the he-FH phenotype is encoun-
tered more often than the homozygous phenotype
due to rapid progression of coronary artery disease
in the homozygous patient population. The in-
vestigators therefore sought to determine the preva-
lence of CAVD in patients with he-FH by measuring
the amount of calciﬁcation burden via computed to-
mography measurements of the coronary artery and
aortic valve, low-density lipoprotein receptor (LDLR)
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royalty payments to the inventor.function, and lipid levels and assessing their associ-
ation with CAVD.
LDL RECEPTOR DENSITY
The investigators discovered that the prevalence of
aortic valve calciﬁcation (AoVC) and the AoVC score
(median [interquartile range]) were both higher in
patients with he-FH than in control subjects: 41%
versus 21%, respectively (p < 0.001) and 51 (9 to 117)
versus 21 (3 to 49) (p ¼ 0.007) (3). LDLR-negative
mutational he-FH was the strongest predictor of the
AoVC score (odds ratio: 4.81; 95% conﬁdence inter-
val: 2.22 to 10.40; p < 0.001). He-FH was associated
with a high prevalence and a large extent of sub-
clinical AoVC, especially in patients with LDLR-
negative mutations, compared with the control
subjects. Moreover, the AoVC scores increased faster
with age in the LDLR-negative he-FH patients than
in the LDLR-defective he-FH patients.
CALCIFICATION DENSITY
The LDLR-negative mutation carrier status was a
strong predictor of the extent of AoVC (3). The asso-
ciation between coronary artery calciﬁcation and
AoVC was associated with a higher prevalence of
AoVC, both in patients with he-FH and in control
subjects. The authors hypothesized that the high
level of coronary artery calciﬁcation may be due to
confounding variables such as differences in statin
therapy in the he-FH population versus the control
population. The concept of 2 different phases of AoVC
progression is not only essential but could explain the
discordant ﬁndings. The National Heart, Lung, and
Blood Institute Aortic Stenosis Working Group for
CAVD (1) also emphasized this concept in early valve
sclerosis versus late valve stenosis.
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Compared with he-FH patients with LDLR-defective
mutations, patients with LDLR-negative mutational
he-FH had higher levels of total cholesterol and
maximum untreated low-density lipoprotein choles-
terol (3). In addition, he-FH patients with LDLR-
negative mutations began statin treatment at a
younger age and used statins for a longer period of
time. Figure 1 illustrates the results of the study in
patients with he-FH, including the effect of func-
tional low-density lipoprotein (LDL) receptors and
proportional increases in LDL with the degree of
AoVC.
To the best of our knowledge, this study by ten
Kate et al. (3) is the ﬁrst to correlate in patients the
role of LDL and the effect of the LDL receptor
genetic contribution in terms of phenotypic ex-
pression of calciﬁcation in the valve and in the
coronary arteries. The LDL-density theories (4–6)
provide a hemodynamic explanation for why
abnormal calciﬁcation develops secondary to high
LDL density concentration up-regulating osteo-
genesis. The effect of ﬂuid ﬂow in the heart is
responsible for the variable phenotype expression,
depending on the radius of the speciﬁc anatomic
location in the heart (i.e., artery vs. valve).FIGURE 1 The LDL-Density-Gene Effect
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(A) The control heart with the normal low-density lipoprotein receptor (L
and mild calciﬁc aortic valve disease. (C) Heterozygous familial hyperch
disease. þ ¼ a semi-quantitative measurement of approximately 10% e
artery calciﬁcation; LDL ¼ low-density lipoprotein.Fluid hemodynamics in the heart depends on
multiple factors, as derived by the Bernoulli equation
for ﬂuid ﬂow (7). Bernoulli described ﬂow through a
column as being directly proportional to the change
in pressure across the column and indirectly propor-
tional to the resistance. The formula for ﬂow through
the heart is similar to Ohm’s law for electricity, as
shown in Equation 1.
Q ¼ DP
R
Equation 1
The entire formula for resistance for steady-state ﬂow
through a circular tube is shown in Equation 2, where
h ¼ viscosity and r ¼ radius of the tube.
R ¼ 8hL
pr4
Equation 2
Equations 1 and 2 can be combined to provide the
ﬂow rate through a circular tube in terms of a pres-
sure drop, which is described as Poiseuille’s law:
Q ¼ pr
4
8hL
DP Equation 3
The differences in the rate of ﬂuid ﬂow depend
on the radius of the anatomic structure, which is
inversely proportional to the resistance. In addition,
it is important to note the inverse r4 dependence offective Mutation
 Function: Partial
LDLR: Negative Mutation
Receptor Function: NONE
eated LDL 232 mg/dl Max untreated LDL 309 mg/dl
+
+
CAC ++++
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DLR). (B) Heterozygous familial hypercholesterolemia–defective receptor mutation
olesterolemia–negative receptor mutation and severe calciﬁc aortic valve
ffect; AoVC ¼ aortic valve calciﬁcation; density ¼ concentration; CAC ¼ coronary
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halved, the pressure drop for a given ﬂow rate and
viscosity is increased by a factor of 16, because the
ﬂow rate is then proportional to the fourth power of
the radius. The LDL-Density-Radius Theory (4) and
the LDL-Density-Pressure Theory (5) provide the
molecular hypothesis of the role of lipids in the dif-
ferentiation of valve myoﬁbroblasts into osteoblast-
like cells responsible for the calcifying phenotype.
Expression of the calciﬁcation in the coronary artery
(8) occurs at a faster rate than the aortic valve sec-
ondary to the effect of the radius in these 2 anatomic
locations in the heart.
The present study (3) measured the level of calci-
ﬁcation, and the results correlate the LDL concen-
tration, LDL receptor gene expression, and ﬁnally a
Mendelian randomization analysis to suggest a causal
role of LDL-C in beginning aortic valve pathology.
The ﬁrst case report to demonstrate by histology
the presence of atherosclerosis in the aortic valve
is in a post-mortem analysis of a patient’s aortic
valve who had the diagnosis of familial hypercholes-
terolemia (9).
If atherosclerosis is an initiating event in this pa-
tient population, would lipid-lowering strategies be
effective for the slowing of disease progression?
In the present study (3), patients with he-FH were
exposed to extremely high levels of LDL before statintreatment, especially those with mutational he-FH.
Since these patients were ﬁrst diagnosed with hy-
percholesterolemia, they have been treated with
statins; this approach dramatically lowered LDL-C
levels and thereby reduced the predictive value of
LDL-C toward AoVC. The authors (3) proposed that
the beneﬁts of the statins are for patients who
received the statins early in the atherosclerotic pro-
cess (9), before the development of calciﬁcation and
eventually severe stenosis. Furthermore, they hy-
pothesized that the results of randomized controlled
trials (6) that tested the effect of statins in CAVD may
be due to the initiation of treatment in patients with
advanced calciﬁc disease.
In conclusion, the present study (3) is the ﬁrst to
combine biochemical analysis with genetic LDL re-
ceptor function and the calcifying phenotype in the
heart. The study further conﬁrms the hypothesis
regarding the possible modiﬁcation and slowing
of CAVD progression with the use of long-term lipid
lowering if the therapy is initiated in the early stages
of pre-clinical CAVD, the atherosclerotic phase (9).
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